Specifically, the recovery of the Th17 compartment, which is severely and permanently damaged during HIV-1 infection, might benefit from therapies including IL-21 treatment, manipulation of IDO1-mediated Trp metabolism, or microbiome-targeted interventions. The gene discussed is IDO1; the disease is HIV-1 infection.